A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 13
- Registration Number
- NCT05093322
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Childrens Hospital Orange County, Orange, California, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Open-label Study of Surufatinib in Japanese Patients
- Conditions
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 36
- Registration Number
- NCT05077384
- Locations
- 🇯🇵
Kagawa University Hospital, Kagawa, Japan
🇯🇵Tohoku University Hospital, Sendai, Japan
🇯🇵Kyushu University Hospital, Fukuoka, Japan
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 47
- Registration Number
- NCT04908046
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Expanded Access Program of Surufatinib
- Conditions
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Hutchmed
- Registration Number
- NCT04814732
- Locations
- 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Mercy Medical Center, Medical Oncology & Hematology, Baltimore, Maryland, United States
🇺🇸Avera Cancer Institute, Sioux Falls, South Dakota, United States
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 75
- Registration Number
- NCT04764474
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇪🇸Clinica Universidad de Navarra, Pamplona, Navarra, Spain
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 90
- Registration Number
- NCT04762602
- Locations
- 🇪🇸
Hospital de la Santa creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Open-Label Surufatinib in European Patients With NET
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 78
- Registration Number
- NCT04579679
- Locations
- 🇫🇷
CHU Bordeaux, Pessac, France
🇺🇸Stony Brook Cancer Center, Stony Brook, New York, United States
🇬🇧Sarah Cannon Research Institute, London, United Kingdom
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 135
- Registration Number
- NCT04579757
- Locations
- 🇺🇸
Arizona Oncology Associated, PC-HOPE, Tucson, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Johns Hopkins University - Sibley Memorial Hospital, Washington, District of Columbia, United States
Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 128
- Registration Number
- NCT04353375
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 3005
- Registration Number
- NCT04005066
- Locations
- 🇨🇳
Shanghai Dongfang Hospital, Shanghai, China